Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency.
Vascular restenosis is one of the major concerns for the management of coronary artery disease using therapeutic vascular procedures. Treatments with thrombin-specific inhibitors, hirudin or hirulog-1, reduced ischemic events in coronary artery disease patients. Early started and prolonged infusions of these thrombin inhibitors partially prevented balloon catheter injury induced restenosis or neointima formation in experimental animal models, but increased the bleeding tendency. Hirulog-like peptide (HLP) was rationally designed to enhance the inhibition of the binding of thrombin to its receptor with less interruption of coagulation activity in comparison to hirulog-1. A single infusion of HLP for 4 h started 0.5 h before balloon catheter injury reduced neointima formation by 36% in rat carotid artery compared to vehicle controls. Tail bleeding time and activated partial thromboplastin time during HLP infusion were not significantly different from vehicle controls, but were significantly shorter than during heparin or hirulog-1 infusion. HLP treatment attenuated the expression of platelet-derived growth factor in the neointima of injured arteries. HLP also inhibited thrombin-induced thymidine incorporation in cultured baboon aortic smooth muscle cells. The findings suggest that HLP may substantially inhibit balloon catheter injury induced neointima formation without noticeable increase in bleeding tendency in rats. The inhibition by HLP of the expression of platelet-derived growth factor and of the smooth muscle cell proliferation in the vascular wall potentially contributes to the preventive effect of the new thrombin inhibitor on injury-induced neointima formation in the vascular wall.
Xue
M
M
Department of Internal Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Ren
S
S
Welch
S
S
Shen
G X
GX
D000800:Angioplasty, Balloon / Q000009:adverse effects*; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001760:Bleeding Time; D020212:Carotid Artery Injuries / Q000188:drug therapy* / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004195:Disease Models, Animal; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006490:Hemostatics / Q000494:pharmacology; D006629:Hirudins / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000166:cytology / Q000378:metabolism; D010314:Partial Thromboplastin Time; D010446:Peptide Fragments / Q000494:pharmacology*; D010982:Platelet-Derived Growth Factor / Q000032:analysis / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology*; D013917:Thrombin / Q000494:pharmacology; D017539:Tunica Intima / Q000737:chemistry / Q000293:injuries / Q000378:metabolism
D000925:Anticoagulants; D006490:Hemostatics; D006629:Hirudins; D010446:Peptide Fragments; D010982:Platelet-Derived Growth Factor; D011994:Recombinant Proteins; C479171:hirulog-like peptide; D013917:Thrombin; C074619:bivalirudin